NVIDIA’s Healthcare Stack Is the Picks and Shovels Play You’ve Been Waiting For
NVIDIA has assembled a comprehensive AI infrastructure stack for healthcare, encompassing BioNeMo, MONAI, Isaac for Healthcare, Holoscan, Parabricks, Clara and NIM. Its 2026 State of AI in Healthcare survey shows 70% of organizations actively using AI, with generative models now the dominant workload (69%). The platform accelerates drug discovery, medical imaging, genomics and edge‑device inference, turning AI from experimental pilots into production‑grade services. Investors and founders see NVIDIA’s stack as the essential “picks‑and‑shovels” layer driving the next wave of health‑tech value creation.
The Ways Pharma Leaders Are Rewiring Their Organizations for Launch Success
Pharma executives face mounting pressure to deliver faster, more successful product launches amid volatile markets and tighter timelines. Inizio Ignite’s Global President Remco op den Kelder argues that traditional static launch plans must give way to agile, data‑driven execution models....
Dose by Design: Pharmaceutical 3D Printing and the Future of Pediatric Compounding
The article charts the transition of pharmaceutical 3D printing from research pilots to routine pharmacy practice, focusing on pediatric compounding. Companies such as FabRx and CurifyLabs have built platforms that let pharmacists print chewable tablets, gels, and mini‑tablets tailored to...
Women’s Hereditary Cancer Testing: From Specialist to Self-Refer
Direct‑to‑consumer genetic testing is reshaping how women assess hereditary cancer risk, allowing them to bypass the traditional NHS referral pathway that required GP and genetics team approval. Private providers such as Jeen Health now offer clinically validated panels via at‑home...
A Gut Microbiome Response to Low Protein Intake Drives Beneficial Browning of Fat Tissue
Researchers have shown that low‑protein diets (LPDs) stimulate the conversion of white adipose tissue into thermogenic beige fat, mirroring effects seen with cold exposure or β‑adrenergic activation. The browning response depends on specific gut microbes; germ‑free mice fail to brown,...
Can Damage to a Stressed Cell Be Reversed?
Soley Therapeutics’ co‑founder and CEO Dr. Yerem Yeghiazarians explained the company’s novel strategy of using small‑molecule drugs to reverse cellular stress rather than targeting a specific virus or gene. The platform aims to restore function in stressed cells implicated in non‑oncology...
Healing Wounded Skin without Scarring? Preclinical Research Shows Promise
Harvard researchers uncovered that post‑natal skin scarring is driven by fibroblast‑produced Cxcl12, which triggers excessive nerve growth that blocks full tissue regeneration. By deleting Cxcl12 or applying Botox to suppress local nerve signaling, mice healed wounds without scars, restoring all...
Right Through the Skull
Researchers have unveiled a novel calvarial delivery platform that injects drug‑laden nanoparticles into the skull’s bone marrow. Immune cells within the diploic space capture the particles and migrate across skull‑meninges channels, ferrying the therapeutic cargo into the brain. In mouse...
Cost of Cultured Meat: Workshop, Modeling, Resources, Feedback
The Unjournal is hosting an online workshop in late April/early May 2026 to refine cost projections for cultivated meat, especially cultured chicken, using an interactive Monte Carlo model. Participants—including bioprocess engineers, cell biologists, animal‑welfare funders, and industry practitioners—will shape belief‑elicitation surveys...
Efforts to Treat Neurodegenerative Disease by Altering the Gut Microbiome
Research increasingly shows that gut microbiome composition influences brain health, with age‑related dysbiosis linked to Alzheimer’s and Parkinson’s disease. Animal studies demonstrate that probiotic strains such as Lactobacillus and Bifidobacterium can reduce neuroinflammation and improve cognitive markers, while fecal microbiota...
Pharmaceutical Executive Daily: Eli Lilly Presses U.K. Government to Raise NHS Drug Pricing
Eli Lilly is pressuring the U.K. government to raise NHS drug prices and eliminate the VPAG rebate scheme before it resumes new investment in Britain. The company is also exploring outcome‑based pricing for its anti‑obesity medicines. In parallel, Lilly struck a...
What if Deleting the Oncogenic Protein Is the Wrong Move?
The article questions the prevailing belief that fully degrading oncogenic proteins outperforms merely inhibiting them. While inhibition has become a cornerstone of targeted cancer therapy, the piece argues that outright removal can trigger unforeseen biological responses. It highlights that protein...
Avutometinib and Defactinib
The FDA granted accelerated approval to the oral co‑pack Avutometinib and Defactinib for adults with KRAS‑mutated, recurrent low‑grade serous ovarian cancer (LGSOC) after prior therapy. The regimen pairs a RAF/MEK inhibitor with a FAK inhibitor, marking a rare “novel‑novel” combination...
InvestorTalk Alert: Brent Willis From Voyageur Pharmaceuticals Ltd. To Host on Tuesday, March 31, 2026
InvestorNews announced an InvestorTalk on March 31, 2026 at 9 AM EST featuring Brent Willis, President and CEO of Voyageur Pharmaceuticals Ltd. (TSXV:VM). Voyageur is advancing a vertically integrated strategy to produce barium and iodine contrast agents, highlighted by a 132,000‑tonne, 98.8% pure barium...
Prilenia and Ferrer Announce First Participant Enrolled in the “PREVAiLS” Phase 3 Study of Pridopidine in ALS
Prilenia Therapeutics and Ferrer have enrolled the first participant in PREVAiLS, a pivotal Phase 3, 500‑patient, randomized, placebo‑controlled trial of the sigma‑1 receptor agonist pridopidine for rapidly progressive ALS. The study, launched at Mass General Brigham, will span 48 weeks with...
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform
Meiji Seika Pharma announced a strategic investment in U.S. biotech Centivax to accelerate its universal influenza vaccine, Centi‑Flu 01, currently in Phase 1 trials. The partnership leverages Meiji’s pharmaceutical expertise and Centivax’s computational immune‑engineering platform to target conserved viral regions, aiming for...
Biocytogen Grants Taisho Pharmaceutical a License to Its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform
Biocytogen has licensed its RenNano® fully human heavy‑chain‑only antibody discovery platform to Japan’s Taisho Pharmaceutical, granting access to RenNano mice for in‑vivo generation and screening of VHH candidates. The agreement, whose financial terms remain undisclosed, adds to Biocytogen’s expanding portfolio...
Module 3, Section 1: HitID Screens
The module introduces HitID screens, outlining key strategies for early-stage drug discovery. It references recent literature on medicinal chemistry optimization, successful hit‑to‑clinical transitions, DNA‑encoded library (DEL) approaches, ultra‑low‑molecular‑weight crystallographic screening, and fragment‑based drug discovery (FBDD). By consolidating these sources, the...
A Novel G9a Inhibitor Reduces Symptoms in Mouse Models of Alzheimer's Disease
Researchers have unveiled FLAV-27, a novel G9a histone methyltransferase inhibitor that readily crosses the blood‑brain barrier and exhibits subnanomolar potency. The compound demonstrates high selectivity for G9a over related enzymes and a favorable safety profile, addressing the limitations of earlier...
Reviewing the Aging of Heart Muscle
Researchers review the biological mechanisms behind cardiac aging, highlighting molecular changes such as mitochondrial dysfunction, non‑coding RNA activity, and cellular senescence that impair myocardial energetics and regeneration. The article links these alterations to clinical outcomes like fibrosis, hypertrophy, valve calcification,...
Pharma Pulse: A Call for U.K. Pricing Reform and the Latest FDA-Approved Biosimilar for Bone Health
Eli Lilly is urging the United Kingdom to overhaul its drug‑pricing framework, warning that persistently low prices could deter future investment and calling for outcomes‑based reimbursement models, especially for obesity therapies. At the same time, the U.S. Food and Drug Administration...
FDA Launches New AI-Powered System to Track Drug and Vaccine Side Effects
The FDA launched the AI‑powered Adverse Event Monitoring System (AEMS) on March 11, 2026, consolidating VAERS, FAERS and other databases into a single, real‑time platform. AI automates data entry and categorization, replacing quarterly updates with instant reporting. Early testing showed...
Why Rocket Pharmaceuticals (RCKT) Got a Commercial Boost From FDA Approval of KRESLADI
Rocket Pharmaceuticals received FDA approval on March 27 for KRESLADI, its first marketed product and the first gene therapy for a rare pediatric disorder. The clearance also awarded the company a Rare Pediatric Disease Priority Review Voucher, which can be...
Why Allogene Therapeutics (ALLO) Says Its Lead Cancer Program Is Still on Track in 2026
Allogene Therapeutics announced that its lead CAR‑T candidate cema‑cel remains on schedule in the pivotal Phase 2 ALPHA3 trial for first‑line consolidation of large B‑cell lymphoma, now enrolling at more than 60 sites worldwide. An interim futility analysis is set for...
Why Aardvark Therapeutics (AARD) Paused Late-Stage ARD-101 Trials After Cardiac Findings
Aardvark Therapeutics announced on March 23, 2026 that it is voluntarily pausing its Phase 3 HERO trial of ARD‑101 for Prader‑Willi syndrome and the ARD‑201 obesity program while it consults the FDA. The decision follows cardiac findings in healthy‑volunteer studies, where...
Patenting Stem Cell Therapies in the US: The Role and Risks of Product-by-Process Claims (Restem v Jadi Cell)
The U.S. Federal Circuit affirmed that product‑by‑process claims for stem‑cell therapies are novel when the underlying product itself is novel, rejecting Restem LLC’s challenge to US 9803176 covering an umbilical‑cord‑derived mesenchymal stem cell (MSC) product called JadiCell. The court interpreted the...
Weekly Reads: Gattaca Stack, Animal Sacks, Custom iPS Cells, ImmunityBio FDA Warning, Mouse Cloning Limit
Weekly reads highlight several frontier biotech developments. The Gattaca Stack, a new database, tracks firms working on embryo models and artificial‑womb technologies. R3 Bio’s stem‑cell “organ sacks” aim to replace animal testing and could evolve into human organ bags, while...
Kardigan Announces Positive Phase 2 Data for Tonlamarsen in Patients with Uncontrolled Hypertension Presented as Late-Breaker at ACC.26 and Simultaneously...
Kardigan reported positive Phase 2 data for its antisense drug tonlamarsen in the KARDINAL trial, showing a dose‑dependent 67% reduction in plasma angiotensinogen and a mean 6.7 mmHg drop in office systolic blood pressure after 20 weeks. Both a single 90 mg dose...
Arrowhead Pharmaceuticals Presents New Long-Term Efficacy and Safety Data for Plozasiran Across a Spectrum of Hypertriglyceridemia at the American College...
Arrowhead Pharmaceuticals presented two‑year open‑label extension data for plozasiran at the ACC 75th session, showing an 83% median triglyceride reduction in severe hypertriglyceridemia and 96% of patients dropping below the 500 mg/dL pancreatitis threshold. No adjudicated acute pancreatitis events occurred, and...
GMO Seeds Sold to Home Gardeners
Biotech startup backed by a former Syngenta executive began selling genetically modified purple tomato seeds to home gardeners in 2024. The product, marketed as a high‑yield, disease‑resistant heirloom alternative, is the first GMO seed line directly available to consumers. Distribution...
Open Label Outpatient Switch Study Demonstrates Symptom Stability During Transition From Oral Atypical Antipsychotics to Cobenfy™ (Xanomeline and Trospium Chloride)
Bristol Myers Squibb reported Phase 4 data showing that adults with schizophrenia can switch from oral atypical antipsychotics to Cobenfy (xanomeline‑trospium) without loss of symptom control. In an 8‑week open‑label trial, 86% of 105 patients completed the study, and mean PANSS...
Statin Safety and Efficacy: What Recent Studies Reveal
Recent meta‑analyses of roughly 100,000‑plus adults confirm that statins and other cholesterol‑lowering drugs cut cardiovascular events by about 30 percent relative risk, delivering an absolute 2 percent mortality benefit over four years—equivalent to one life saved for every 50 treated. The safety...
MiniMed Unveils MiniMed Flex, Its Smallest Insulin Pump Yet
MiniMed secured FDA clearance for the MiniMed Flex, its smallest insulin pump yet, featuring a fully smartphone‑controlled, screenless design. The pocket‑sized device is roughly half the size of the 780G and holds a 300‑unit insulin reservoir while integrating continuous glucose...
LEO Pharma Announces New Long-Term Data for SPEVIGO® (Spesolimab-Sbzo) Injection in Adults with Generalized Pustular Psoriasis at AAD 2026
LEO Pharma presented long‑term results from the five‑year EFFISAYIL ON extension, showing subcutaneous SPEVIGO® reduced generalized pustular psoriasis (GPP) flares from an average of two per year to 0.13, with 74.6% of patients experiencing no flares over three years. Intravenous SPEVIGO...
Integrating Computational and Experimental Techniques to Decipher Neuronal Heterogeneity
Andreas Pfenning’s lab at Carnegie Mellon is merging single‑nucleus RNA‑seq, ATAC‑seq and high‑resolution spatial transcriptomics to map neuronal and glial subtypes without the shape‑bias of traditional droplet methods. AI algorithms then design cell‑type‑specific enhancers, which are screened on the 10x...
Brightseed Launches Enterprise AI Solution to Streamline Formulation and Manufacturing Success
Brightseed unveiled the world’s first clinically validated enterprise AI platform, designed to unite discovery, development, and commercialization for health‑science products. The system targets the industry’s 75% early‑stage failure rate by eliminating fragmented workflows and late‑stage risk discovery. Powered by the...
1389A. I Injected Stem Cells Into My Penis (Here’s What Happened)
Dave Asprey visited Costa Rica’s RMI Clinic to undergo a neurocognitive protocol that blends functional MRI mapping, neuronavigation, transcranial magnetic stimulation, focused ultrasound and mesenchymal stem‑cell infusion. The treatment targets hypofunctioning brain regions with millimeter precision and is followed by...
Pharma Pulse: Commercial Risks of the NDC-12 Transition and FDA Approval of Avlayah for Hunter Syndrome
The pharmaceutical industry faces commercial risk as it prepares for the 2033 transition to a uniform 12‑digit NDC format, with experts warning that thousands of zero‑prefix collisions could trigger PBM claim rejections, disrupt patient‑hub enrollments, and corrupt market‑intelligence data. Simultaneously,...
Why Are Cancer Cells Able to Thrive in Conditions That Other Cells Cannot?
Soley Therapeutics, founded by clinician‑scientist Yerem Yeghiazarians and a cancer biologist, built a decade‑long, image‑based platform that treats cells as sophisticated sensors of their micro‑environment. The technology decodes how cells decide to live or die under low‑oxygen, nutrient‑poor conditions—an environment...
How Anesthetics Destabilize the Brain: Scientists Stumble upon Common Mechanism
MIT researchers discovered that three widely used anesthetics—propofol, ketamine and dexmedetomidine—produce an identical destabilization of brain dynamics, measurable as a loss of dynamic stability. Using EEG‑based perturbation analysis, they showed that despite distinct molecular targets, each drug pushes the brain...
Agenus to Host March 2026 Stakeholder Webcast Harnessing the Immune System to Advance BOT + BAL Across Tumor Types and...
Agenus announced a March 31, 2026 stakeholder webcast to detail progress on its botensilimab and balstilimab (BOT + BAL) immunotherapy program. The company highlighted clinical durability across multiple tumor types, with roughly 1,200 patients treated with botensilimab and over 900 with balstilimab...
Frank Harrell on Why and How to Do Bayes for Clinical Trials and the Recent FDA Draft Guidelines
Frank Harrell, a former FDA statistician, responded to recent JAMA commentary on the agency’s draft guidance promoting Bayesian methods for clinical trials. He highlighted that while the guidance is a step forward, FDA reviewers still rely on traditional frequentist approaches...
Pharmaceutical Executive Daily: Trump Administration Misses Deadline to Nominate Permanent CDC Director
The Trump administration failed to meet the 210‑day deadline to nominate a permanent CDC director, leaving the agency without confirmed leadership for most of the second term. Meanwhile, the FDA granted accelerated approval to Denali Therapeutics’ Avlayah, the first enzyme...
Cellular Senescence and Senotherapeutics: The Expert Roundup
Cellular senescence has become a focal point for longevity medicine, prompting a surge of senolytic and senomorphic drug development. Pioneering studies showed that clearing senescent cells can extend healthspan, leading biotech firms like Rubedo, SENISCA, Deciduous Therapeutics, and Arda Therapeutics...
Development of an Ultra-Sensitive Human Cardiac Troponin I Sandwich ELISA
Exazym®'s BOLD amplification technology boosts the sensitivity of a human cardiac troponin I sandwich ELISA by 180‑fold, lowering the detection limit to 0.07 pg/mL. The webinar presented by Cavidi’s Peter Stenlund shows how the method integrates into standard ELISA workflows with...
Autoimmune Immunotherapy Is Shifting Upstream: AnaptysBio on Targeting Pathogenic Immune Cells
Autoimmune drug development is moving upstream, targeting pathogenic immune cells rather than single cytokines. AnaptysBio’s Chief Medical Officer, Paul Lizzul, highlighted the company’s cell‑selective immunomodulation strategy, including CD122 antagonism that modulates both CD4 helper and CD8 cytotoxic T cells. Early‑phase...
World-First Living ‘Robots’ Develop Functional Nervous Systems
Researchers at the Wyss Institute have created the first living robots, called neurobots, that develop functional nervous systems from implanted neuronal precursor cells. The neurobots, built from frog embryonic cells, self‑organize neural networks that reshape their morphology, boost motility, and...
LPBF Prints Zinc–Silver–Copper Alloys For Biodegradable Implants
Researchers used laser powder bed fusion (LPBF) to 3D‑print zinc‑silver‑copper alloys and demonstrated in‑vitro cytocompatibility, indicating the material could serve as a biodegradable implant. Zinc offers a middle‑ground degradation rate between magnesium and iron, while silver and copper add antimicrobial...
